Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave

Respir Investig. 2021 Sep;59(5):661-665. doi: 10.1016/j.resinv.2021.04.010. Epub 2021 May 28.

Abstract

In this study, we compared the incidence of pneumomediastinum in coronavirus disease (COVID-19) patients during the ascending phases of the 1st and 2nd epidemic waves. Crude incidence was higher during the 2nd wave at a quasi-significant level (0.68/1000 vs. 2.05/1000 patient-days, p = 0.05). When restricting the analysis to patients who developed pneumomediastinum during noninvasive ventilation, the difference became clearly significant (0.17/1000 vs 1.36/1000 patient-days, p = 0.039). At logistic regression, predisposing factors (p = 0.031), and COVID-19 radiological severity (p = 0.019) were independently associated with pneumomediastinum. Mortality in patients with pneumomediastinum was 87.5%. However, pneumomediastinum seemed to be related to a generally worse disease presentation in hospitalized patients during the 2nd wave, rather than to a separate pattern of disease.

Keywords: Barotrauma; COVID-19; Pneumomediastinum; Pneumothorax.

MeSH terms

  • COVID-19* / complications
  • Humans
  • Incidence
  • Mediastinal Emphysema* / diagnostic imaging
  • Mediastinal Emphysema* / epidemiology
  • Mediastinal Emphysema* / etiology
  • Pneumothorax
  • SARS-CoV-2